BR0316296A - Compostos lapacone e seus métodos de uso - Google Patents
Compostos lapacone e seus métodos de usoInfo
- Publication number
- BR0316296A BR0316296A BR0316296-6A BR0316296A BR0316296A BR 0316296 A BR0316296 A BR 0316296A BR 0316296 A BR0316296 A BR 0316296A BR 0316296 A BR0316296 A BR 0316296A
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- lapacone
- methods
- treatment
- psoriasis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
- C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D335/08—Naphthothiopyrans; Hydrogenated naphthothiopyrans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/92—Naphthofurans; Hydrogenated naphthofurans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/78—Ring systems having three or more relevant rings
- C07D311/92—Naphthopyrans; Hydrogenated naphthopyrans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D327/00—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms
- C07D327/02—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms one oxygen atom and one sulfur atom
- C07D327/06—Six-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/74—Naphthothiophenes
Abstract
"COMPOSTOS LAPACONE E SEUS MéTODOS DE USO". A invenção fornece análogos e derivados do lapacone assim como seus métodos de uso. Esses compostos podem ser utilizados nas composições farmacêuticas para o tratamento ou prevenção de distúrbios de proliferação celular. Esses compostos podem também ser utilizados no tratamento ou psoríase ou câncer ou condições pré-cancerosas.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US42728302P | 2002-11-18 | 2002-11-18 | |
US10/622,854 US20040209942A1 (en) | 2002-07-17 | 2003-07-17 | Activated checkpoint therapy and methods of use thereof |
PCT/US2003/022631 WO2004007531A2 (en) | 2002-07-17 | 2003-07-17 | Activated checkpoint therapy and methods of use thereof |
PCT/US2003/037219 WO2004045557A2 (en) | 2002-11-18 | 2003-11-18 | Novel lapachone compounds and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0316296A true BR0316296A (pt) | 2005-12-13 |
Family
ID=34375156
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0316296-6A BR0316296A (pt) | 2002-11-18 | 2003-11-18 | Compostos lapacone e seus métodos de uso |
Country Status (12)
Country | Link |
---|---|
US (1) | US20040266857A1 (pt) |
EP (1) | EP1567515A4 (pt) |
JP (1) | JP2006508147A (pt) |
CN (1) | CN1729183A (pt) |
AR (1) | AR056613A1 (pt) |
AU (1) | AU2003295738A1 (pt) |
BR (1) | BR0316296A (pt) |
CA (1) | CA2506340A1 (pt) |
EA (1) | EA200500849A1 (pt) |
MX (1) | MXPA05005314A (pt) |
TW (1) | TW200510367A (pt) |
WO (1) | WO2004045557A2 (pt) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7361691B2 (en) | 2002-12-02 | 2008-04-22 | Arqule, Inc. | Method of treating cancers using β-lapachone or analogs or derivatives thereof |
CA2546445A1 (en) | 2003-11-26 | 2005-06-16 | Arqule, Inc. | Use of beta-lapachone for protecting against radiation injury |
JP2007523191A (ja) * | 2004-02-20 | 2007-08-16 | アークル・インコーポレーテツド | 血液腫瘍の治療のためのβ−ラパコンの使用 |
US20050187288A1 (en) * | 2004-02-20 | 2005-08-25 | Chiang Li | Beta-lapachone and methods of treating cancer |
EP2033638A2 (en) | 2004-02-20 | 2009-03-11 | Arqule, Inc. | Beta-lapachone for the treatment of pancreatic cancer |
CA2556794A1 (en) * | 2004-02-20 | 2005-09-09 | Arqule, Inc. | Use of beta-lapachone as a broad spectrum anti-cancer agent |
EP1732539A2 (en) | 2004-02-20 | 2006-12-20 | Arqule, Inc. | Use of beta-lapachone for the treatment of colon cancer |
EP1722775A1 (en) | 2004-02-20 | 2006-11-22 | Arqule, Inc. | Use of beta-lapachone for treating hematologic tumors |
WO2005082353A2 (en) * | 2004-02-20 | 2005-09-09 | Arqule, Inc. | Use of beta-lapachone for treating or preventing cancer |
US8614228B2 (en) | 2004-08-11 | 2013-12-24 | Arqule, Inc. | Quinone prodrug compositions and methods of use |
WO2006020719A2 (en) | 2004-08-11 | 2006-02-23 | Arqule, Inc. | Aminoacid conjugates of beta - lapachone for tumor targeting |
CA2594234A1 (en) | 2005-01-07 | 2006-07-27 | Arqule, Inc. | Compositions for modulation of parp and methods for screening for same |
WO2006128120A2 (en) * | 2005-05-26 | 2006-11-30 | Arqule, Inc. | Novel lapachone compounds and methods of use thereof |
EP2035435A1 (en) * | 2006-05-26 | 2009-03-18 | Arqule, Inc. | Novel lapachone compounds and methods of use thereof |
TW200824692A (en) | 2006-08-21 | 2008-06-16 | Arqule Inc | Novel lapachone compounds and methods of use thereof |
EP2137168B1 (en) * | 2007-03-16 | 2016-09-14 | Lankenau Institute for Medical Research | Novel ido inhibitors and methods of use thereof |
JP2010526072A (ja) | 2007-04-30 | 2010-07-29 | アークル インコーポレイテッド | キノン化合物のヒドロキシスルホナートおよびその使用 |
WO2009051752A1 (en) * | 2007-10-16 | 2009-04-23 | Arqule, Inc. | Novel lapachone compounds and methods of use thereof |
KR101405823B1 (ko) | 2007-12-24 | 2014-06-12 | 주식회사 케이티앤지생명과학 | 녹내장의 치료 및 예방을 위한 약제 조성물 |
KR20090071829A (ko) * | 2007-12-28 | 2009-07-02 | 주식회사 머젠스 | 신장질환의 치료 및 예방을 위한 약제 조성물 |
KR20090073381A (ko) * | 2007-12-31 | 2009-07-03 | 주식회사 머젠스 | 심장질환의 치료 및 예방을 위한 약제 조성물 |
WO2011152923A1 (en) * | 2010-06-01 | 2011-12-08 | Belle-Aire Fragrances, Inc. | Oral odor control method and product |
WO2017106624A1 (en) | 2015-12-18 | 2017-06-22 | The Board Of Regents Of The University Of Texas System | Napthoquinones, pro-drugs, and methods of use thereof |
KR101735275B1 (ko) | 2016-12-20 | 2017-05-16 | 아주대학교산학협력단 | 베타-라파촌을 포함하는 수면 장애 예방 또는 치료용 조성물 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2011455B (en) * | 1977-12-21 | 1982-03-03 | Ici Ltd | Chemical process |
US5346917A (en) * | 1991-06-10 | 1994-09-13 | Sterling Winthrop Inc. | Thioxanthenone antitumor agents |
US5763625A (en) * | 1995-04-25 | 1998-06-09 | Wisconsin Alumni Research Foundation | Synthesis and use of β-lapachone analogs |
US6245807B1 (en) * | 1995-08-24 | 2001-06-12 | Dana-Farber Cancer Institute | Treatment of human prostate disease |
US5824700A (en) * | 1996-02-20 | 1998-10-20 | Wisconsin Alumni Research Foundation | Ortho-quinone derivatives novel synthesis therefor and their use in the inhibition of neoplastic cell growth |
US5883270A (en) * | 1996-02-20 | 1999-03-16 | Wisconsin Alumni Research Foundation | 4-substituted-1, 2-naphthoquinones and their use in the inhibition of neoplastic cell growth |
EP1181013B1 (en) * | 1999-04-14 | 2006-10-11 | Dana-Farber Cancer Institute, Inc. | Method and composition for the treatment of cancer |
CA2492772A1 (en) * | 2002-07-17 | 2004-01-22 | Chiang J. Li | Activated checkpoint therapy and methods of use thereof |
-
2003
- 2003-11-18 TW TW092132328A patent/TW200510367A/zh unknown
- 2003-11-18 EP EP03786941A patent/EP1567515A4/en active Pending
- 2003-11-18 CN CNA2003801066171A patent/CN1729183A/zh active Pending
- 2003-11-18 BR BR0316296-6A patent/BR0316296A/pt not_active Application Discontinuation
- 2003-11-18 WO PCT/US2003/037219 patent/WO2004045557A2/en active Application Filing
- 2003-11-18 EA EA200500849A patent/EA200500849A1/ru unknown
- 2003-11-18 MX MXPA05005314A patent/MXPA05005314A/es not_active Application Discontinuation
- 2003-11-18 JP JP2004553999A patent/JP2006508147A/ja active Pending
- 2003-11-18 AR ARP030104253A patent/AR056613A1/es not_active Application Discontinuation
- 2003-11-18 AU AU2003295738A patent/AU2003295738A1/en not_active Abandoned
- 2003-11-18 CA CA002506340A patent/CA2506340A1/en not_active Abandoned
-
2004
- 2004-03-26 US US10/810,260 patent/US20040266857A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20040266857A1 (en) | 2004-12-30 |
MXPA05005314A (es) | 2005-10-19 |
JP2006508147A (ja) | 2006-03-09 |
WO2004045557A3 (en) | 2004-08-12 |
CA2506340A1 (en) | 2004-06-03 |
EP1567515A2 (en) | 2005-08-31 |
WO2004045557A2 (en) | 2004-06-03 |
EP1567515A4 (en) | 2008-04-23 |
EA200500849A1 (ru) | 2006-02-24 |
TW200510367A (en) | 2005-03-16 |
AU2003295738A1 (en) | 2004-06-15 |
AR056613A1 (es) | 2007-10-17 |
CN1729183A (zh) | 2006-02-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0316296A (pt) | Compostos lapacone e seus métodos de uso | |
FI953748A (fi) | Yhdisteitä, joilla on sekä voimakas kalsium antagonisti- että antioksidanttiaktiivisuus sekä niiden käyttö solua suojaavina aineina | |
BRPI0418112A (pt) | inibidores de p-38 quinase bicìclico heterocìclicos | |
ME00275B (me) | ω-KARBOKSIARIL SUPSTITUISANI DIFENIL KARBAMIDI KAO INHIBITORI RAF KINAZE | |
MEP36908A (en) | omega-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | |
NO20050807L (no) | Farmasoytiske sammensetninger som innbefatter dekstrometorfan og kinidin for behandling av neurologiske forstyrrelser | |
UY27807A1 (es) | Nuevos derivados de piridazin-3(2h)-ona | |
UY27760A1 (es) | Nuevos derivados de pirrolidinio. | |
ATE253063T1 (de) | 5-ht1f-agonisten | |
ATE231872T1 (de) | Thiazolopyrimidinderivate | |
BR9811482A (pt) | Derivados de 1-(n-fenilaminoalquil)-piperazina substituìda na posição 2 do anel fenìlico | |
GT200300294A (es) | Compuestos de indazol y composiciones farmaceuticas para inhibir proteinquinasas y procedimientos para su uso | |
AR024138A1 (es) | Inhibidores de la proliferacion celular | |
DE502004002571D1 (de) | Substituierte 3-pyrrolidin-indol-derivate | |
CY1108932T1 (el) | Ενωσεις 4-(ετεροκυκλυλ)-βενζολοσουλφοξιμινης για την θεραπευτικη αγωγη φλεγμονωδων ασθενειων | |
DE60220771D1 (de) | Hemmer von cyclinabhängigen kinasen als mittel gegen krebs | |
BR0015416A (pt) | Composições contendo derivados do ácido hidroxieicosa tetraenóico e métodos de uso no tratamento de distúrbios de olhos secos | |
BR0314053A (pt) | Pirazolopiridinas e métodos de obtenção e uso das mesmas | |
BR0015392A (pt) | Lipoxina a4 e seus análogos para o tratamento de olho ressecado | |
DE69528710D1 (de) | 2-substituierte 1,2,5-thiadiazolidin-3-on-1,1-dioxiden, zusammensetzung und deren verwendung | |
YU87202A (sh) | Derivati arilmetilamina koji se koriste kao inhibitori triptaze | |
EP1551392A4 (en) | NOVEL LAPACHO COMPOUNDS AND METHODS OF USE THEREOF | |
AR020563A1 (es) | Compuestos (poli)tia-alquinoicos y sus derivados, composiciones que los incluyen y su utilizacion | |
DE60129829D1 (de) | Zyklisierte benzamid-neurokinin-antagonisten zur verwendung in therapie | |
BR0309996A (pt) | Composto, composição farmacêutica, método de tratar ou melhorar doenças ou condições proliferativas, uso de um composto, e, método de tratar ou melhorar doenças inflamatórias |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |